A major April 2026 milestone showed how quantum computing could begin moving beyond abstract benchmarks and into biomedical research.

On April 16, Wellcome Leap announced that a team led by Finnish quantum-software company Algorithmic, working with Cleveland Clinic and IBM, had won a US$2-million Quantum for Bio prize for demonstrating an end-to-end quantum-classical workflow relevant to cancer-drug simulation.

The Quantum for Bio program was a US$50-million initiative designed to determine whether quantum computing could eventually provide meaningful computational advantages for difficult biological and healthcare problems. Twelve teams initially participated, with six reaching the final phase.

Algorithmiq's project focused on photodynamic therapy, a cancer treatment in which light activates a photosensitive drug. The researchers developed a hybrid quantum-classical workflow for calculating excited-state properties of a photosensitized molecule relevant to this therapy.

To qualify for the US$2-million award, teams had to perform an experimental realization using more than 50 qubits, circuits with depths on the order of 1,000–10,000 operations, and demonstrate a credible path toward future quantum advantage.

However, one distinction is essential: the team did not demonstrate definitive quantum advantage over the best classical methods. Wellcome Leap had offered a separate US$5-million grand prize for that achievement, and no team won it.

That makes the result particularly useful for a balanced assessment of quantum computing.
The experiment shows meaningful progress toward real scientific applications while simultaneously demonstrating how high the threshold for true quantum advantage remains.

Instead of claiming that quantum computers can already discover new cancer drugs, the work establishes something more credible: researchers can now build complete quantum-classical pipelines around medically relevant molecular problems and test those pipelines on real hardware.

As quantum processors improve, these existing workflows could provide a direct route toward increasingly difficult drug-discovery calculations.